BioIVT Acquires ZenBio, Expanding Biospecimen and Cell-Based Services

BioIVT, a multinational research collaborator and supplier of biospecimen solutions for medication and diagnostic development, has purchased ZenBio Inc., a renowned pioneer in the advanced cell products and services market. When BioIVT and ZenBio work together, they will provide pharmaceutical and cosmetics industries with a wider range of services, including primary cell and exosome isolation, skin-based knowledge, and blood products. No financial information was provided.

Richard Haigh, CEO of BioIVT, stated, "Biospecimens and services like primary cell isolation are crucial for developing new pharmaceuticals." "ZenBio's trusted reputation, combined with BioIVT's extensive portfolio and scalability, will allow us to deliver even more quality products and services to scientists and researchers around the world."

ZenBio, a highly renowned science-focused business with its headquarters in Durham, North Carolina, specialises in biospecimens and associated services and is flexible enough to satisfy the demands of researchers while maintaining a strong focus on science. The goal of both BioIVT and ZenBio is to facilitate scientific innovation and discovery by offering superior biospecimens and biotechnology services.

"A common dedication to furthering scientific research has always motivated our collaboration with BioIVT, and we're thrilled to grow this alliance," stated ZenBio President Peter Pieraccini.

This announcement, together with the effective integration of XenoTech, signifies a significant extension of BioIVT's service offering into hitherto untapped toxicity areas. Its consulting staff has also been bolstered by the addition of specialists in primary cells and exosome research.

Christopher Black, Senior Vice President, ADME-Tox, at BioIVT, stated, "This acquisition is critical as it will allow us to more deeply support research with an expanded array of tools, which improves the safety profiles of new pharmaceuticals and cosmeceuticals." "As leaders in our field, adding the ZenBio team enhances our already impressive portfolio, providing researchers with more options and accelerating the time to market for new pharmaceuticals."